The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review

S. M. Swain, P. Vici

Research output: Contribution to journalArticle

Abstract

This article summarizes the views of an expert meeting of cardiologists and oncologists on the use of dexrazoxane in anthracycline-based chemotherapy. Anthracycline-induced cardiotoxicity remains a major concern and new trends in treatment (e.g., combination of an anthracycline with other agents) will ensure that it remains a problem. Dexrazoxane reduces this cardiotoxicity in adults and children with a range of tumor types. Further research may help to identify those patients who are at particular risk of cardiotoxicity and who would benefit the most from dexrazoxane. There are also numerous possibilities for dexrazoxane in other clinical situations, which must be addressed in future trials.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalJournal of Cancer Research and Clinical Oncology
Volume130
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

Dexrazoxane
Anthracyclines
Therapeutics
Drug Therapy
Research
Cardiotoxicity
Neoplasms

Keywords

  • Anthracycline
  • Cancer
  • Cardiotoxicity
  • Dexrazoxane
  • Doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{72e9cbc256344558881db48d7337191c,
title = "The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review",
abstract = "This article summarizes the views of an expert meeting of cardiologists and oncologists on the use of dexrazoxane in anthracycline-based chemotherapy. Anthracycline-induced cardiotoxicity remains a major concern and new trends in treatment (e.g., combination of an anthracycline with other agents) will ensure that it remains a problem. Dexrazoxane reduces this cardiotoxicity in adults and children with a range of tumor types. Further research may help to identify those patients who are at particular risk of cardiotoxicity and who would benefit the most from dexrazoxane. There are also numerous possibilities for dexrazoxane in other clinical situations, which must be addressed in future trials.",
keywords = "Anthracycline, Cancer, Cardiotoxicity, Dexrazoxane, Doxorubicin",
author = "Swain, {S. M.} and P. Vici",
year = "2004",
month = "1",
doi = "10.1007/s00432-003-0498-7",
language = "English",
volume = "130",
pages = "1--7",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment

T2 - Expert panel review

AU - Swain, S. M.

AU - Vici, P.

PY - 2004/1

Y1 - 2004/1

N2 - This article summarizes the views of an expert meeting of cardiologists and oncologists on the use of dexrazoxane in anthracycline-based chemotherapy. Anthracycline-induced cardiotoxicity remains a major concern and new trends in treatment (e.g., combination of an anthracycline with other agents) will ensure that it remains a problem. Dexrazoxane reduces this cardiotoxicity in adults and children with a range of tumor types. Further research may help to identify those patients who are at particular risk of cardiotoxicity and who would benefit the most from dexrazoxane. There are also numerous possibilities for dexrazoxane in other clinical situations, which must be addressed in future trials.

AB - This article summarizes the views of an expert meeting of cardiologists and oncologists on the use of dexrazoxane in anthracycline-based chemotherapy. Anthracycline-induced cardiotoxicity remains a major concern and new trends in treatment (e.g., combination of an anthracycline with other agents) will ensure that it remains a problem. Dexrazoxane reduces this cardiotoxicity in adults and children with a range of tumor types. Further research may help to identify those patients who are at particular risk of cardiotoxicity and who would benefit the most from dexrazoxane. There are also numerous possibilities for dexrazoxane in other clinical situations, which must be addressed in future trials.

KW - Anthracycline

KW - Cancer

KW - Cardiotoxicity

KW - Dexrazoxane

KW - Doxorubicin

UR - http://www.scopus.com/inward/record.url?scp=0742269397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742269397&partnerID=8YFLogxK

U2 - 10.1007/s00432-003-0498-7

DO - 10.1007/s00432-003-0498-7

M3 - Article

C2 - 14564513

AN - SCOPUS:0742269397

VL - 130

SP - 1

EP - 7

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 1

ER -